342 related articles for article (PubMed ID: 15286801)
1. Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis.
Murray RD; Kim K; Ren SG; Chelly M; Umehara Y; Melmed S
J Clin Invest; 2004 Aug; 114(3):349-56. PubMed ID: 15286801
[TBL] [Abstract][Full Text] [Related]
2. In vitro effects of somatostatin on the growth hormone-insulin-like growth factor axis in orange-spotted grouper (Epinephelus coioides).
Wang B; Jia J; Yang G; Qin J; Zhang C; Zhang Q; Sun C; Li W
Gen Comp Endocrinol; 2016 Oct; 237():1-9. PubMed ID: 26526981
[TBL] [Abstract][Full Text] [Related]
3. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile.
Bruns C; Lewis I; Briner U; Meno-Tetang G; Weckbecker G
Eur J Endocrinol; 2002 May; 146(5):707-16. PubMed ID: 11980628
[TBL] [Abstract][Full Text] [Related]
4. SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs.
Weckbecker G; Briner U; Lewis I; Bruns C
Endocrinology; 2002 Oct; 143(10):4123-30. PubMed ID: 12239124
[TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor-I action on growth hormone secretion and messenger ribonucleic acid levels: interaction with somatostatin.
Namba H; Morita S; Melmed S
Endocrinology; 1989 Apr; 124(4):1794-9. PubMed ID: 2564339
[TBL] [Abstract][Full Text] [Related]
6. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro.
Hofland LJ; van der Hoek J; van Koetsveld PM; de Herder WW; Waaijers M; Sprij-Mooij D; Bruns C; Weckbecker G; Feelders R; van der Lely AJ; Beckers A; Lamberts SW
J Clin Endocrinol Metab; 2004 Apr; 89(4):1577-85. PubMed ID: 15070915
[TBL] [Abstract][Full Text] [Related]
7. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes.
Jaquet P; Saveanu A; Gunz G; Fina F; Zamora AJ; Grino M; Culler MD; Moreau JP; Enjalbert A; Ouafik LH
J Clin Endocrinol Metab; 2000 Feb; 85(2):781-92. PubMed ID: 10690891
[TBL] [Abstract][Full Text] [Related]
8. Octreotide inhibits insulin-like growth factor-I hepatic gene expression in the hypophysectomized rat: evidence for a direct and indirect mechanism of action.
Serri O; Brazeau P; Kachra Z; Posner B
Endocrinology; 1992 Apr; 130(4):1816-21. PubMed ID: 1547711
[TBL] [Abstract][Full Text] [Related]
9. The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion.
Murray RD; Kim K; Ren SG; Lewis I; Weckbecker G; Bruns C; Melmed S
J Clin Endocrinol Metab; 2004 Jun; 89(6):3027-32. PubMed ID: 15181094
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin modulates G-CSF-induced but not interleukin-3-induced proliferative responses in myeloid 32D cells via activation of somatostatin receptor subtype 2.
Oomen SP; Ward AC; Hofland LJ; Lamberts SW; Löwenberg B; Touw IP
Hematol J; 2001; 2(5):322-9. PubMed ID: 11920268
[TBL] [Abstract][Full Text] [Related]
11. The effects of GH-releasing hormone/somatostatin on the 5'-promoter activity of the GH gene in vitro.
Morishita M; Iwasaki Y; Onishi A; Asai M; Mutsuga N; Yoshida M; Oiso Y; Inoue K; Murohara T
J Mol Endocrinol; 2003 Dec; 31(3):441-8. PubMed ID: 14664705
[TBL] [Abstract][Full Text] [Related]
12. Modulation of pituitary somatostatin receptor subtype (sst1-5) messenger ribonucleic acid levels by changes in the growth hormone axis.
Park S; Kamegai J; Johnson TA; Frohman LA; Kineman RD
Endocrinology; 2000 Oct; 141(10):3556-63. PubMed ID: 11014208
[TBL] [Abstract][Full Text] [Related]
13. Growth hormone (GH)-stimulated insulin-like growth factor I gene expression is mediated by a tyrosine phosphorylation pathway depending on C-terminal region of human GH receptor in human GH receptor-expressing Ba/F3 cells.
Yoshizato H; Tanaka M; Nakai N; Nakao N; Nakashima K
Endocrinology; 2004 Jan; 145(1):214-20. PubMed ID: 14551225
[TBL] [Abstract][Full Text] [Related]
14. Relative potencies of the somatostatin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells.
Hofland LJ; van Koetsveld PM; Waaijers M; Zuyderwijk J; Lamberts SW
Endocrinology; 1994 Jan; 134(1):301-6. PubMed ID: 7903931
[TBL] [Abstract][Full Text] [Related]
15. Sepsis-induced muscle growth hormone resistance occurs independently of STAT5 phosphorylation.
Hong-Brown LQ; Brown CR; Cooney RN; Frost RA; Lang CH
Am J Physiol Endocrinol Metab; 2003 Jul; 285(1):E63-72. PubMed ID: 12644450
[TBL] [Abstract][Full Text] [Related]
16. Negative regulation of hypothalamic growth hormone-releasing factor messenger ribonucleic acid by growth hormone and insulin-like growth factor I.
Uchiyama T; Kaji H; Abe H; Chihara K
Neuroendocrinology; 1994 May; 59(5):441-50. PubMed ID: 7912818
[TBL] [Abstract][Full Text] [Related]
17. Regulation of growth hormone (GH) secretion by GH-releasing factor, somatostatin, and insulin-like growth factor I in ovine fetal and neonatal pituitary cells in vitro.
Silverman BL; Bettendorf M; Kaplan SL; Grumbach MM; Miller WL
Endocrinology; 1989 Jan; 124(1):84-9. PubMed ID: 2562828
[TBL] [Abstract][Full Text] [Related]
18. Tumor necrosis factor inhibits growth hormone-mediated gene expression in hepatocytes.
Ahmed T; Yumet G; Shumate M; Lang CH; Rotwein P; Cooney RN
Am J Physiol Gastrointest Liver Physiol; 2006 Jul; 291(1):G35-44. PubMed ID: 16574984
[TBL] [Abstract][Full Text] [Related]
19. Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin.
Afargan M; Janson ET; Gelerman G; Rosenfeld R; Ziv O; Karpov O; Wolf A; Bracha M; Shohat D; Liapakis G; Gilon C; Hoffman A; Stephensky D; Oberg K
Endocrinology; 2001 Jan; 142(1):477-86. PubMed ID: 11145612
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide.
Park C; Yang I; Woo J; Kim S; Kim J; Kim Y; Sohn S; Kim E; Lee M; Park H; Jung J; Park S
Endocr J; 2004 Apr; 51(2):227-36. PubMed ID: 15118275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
